Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Need Of Evidence: Medicare Panel Prioritizes Research Efforts

This article was originally published in The Gray Sheet

Executive Summary

Top research priorities for the elderly should include looking at carotid artery stenting, radiation therapy and prognostic markers for cancer, as well as a number of other areas applicable to devices and diagnostics, says the Medicare Evidence Development and Coverage Advisory Committee

You may also be interested in...



CMS’ “Potential” NCD List Gets Stakeholder Support, But Questions Remain

The device industry and other Medicare stakeholders are generally supportive of CMS' recent move to publicize topics it is considering for future national coverage determinations, though some worry that the agency will use the process to limit patient access to technologies

CMS’ “Potential” NCD List Gets Stakeholder Support, But Questions Remain

The device industry and other Medicare stakeholders are generally supportive of CMS' recent move to publicize topics it is considering for future national coverage determinations, though some worry that the agency will use the process to limit patient access to technologies

CMS Plans Response To Industry Concerns Over MedCAC Process

CMS will more fully describe how it intends to use its Medicare Evidence Development and Coverage Advisory Committee to set research priorities, CMS Chief Medical Officer Barry M. Straube said April 30 at a MedCAC meeting in Baltimore

Related Content

UsernamePublicRestriction

Register

MT025472

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel